侵袭性曲霉病当前管理格局
综述指出,侵袭性曲霉病因血或体液培养困难,推动非培养诊断技术发展,包括血液和支气管肺泡灌洗液半乳甘露聚糖检测、血液1,3-β-d-葡聚糖检测及PCR检测曲霉DNA。近几十年对抗原检测优劣认识加深、PCR标准化改善,这些检测正纳入诊疗路径和诊断算法,辅助抗真菌药物管理与疗效预测。
要点
- 血或体液培养阳性率低是侵袭性曲霉病诊断难点。
- 非培养检测包括GM、BDG和PCR检测曲霉DNA。
- 上述检测正纳入诊疗路径,辅助抗真菌药物管理与疗效预测。
核心结论
- 非培养诊断技术(GM、BDG、PCR)正纳入侵袭性曲霉病诊疗路径和诊断算法,辅助抗真菌药物管理与疗效预测。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 血或体液难以培养出曲霉是侵袭性曲霉病诊断长期面临的挑战。
- 检测血液和支气管肺泡灌洗液GM、血液BDG及PCR检测曲霉DNA是非培养诊断方向。
- 近几十年对抗原检测优劣的理解改善,PCR-DNA技术标准化也取得进展。
临床怎么用
- 可将GM、BDG和PCR等非培养检测纳入侵袭性曲霉病诊疗路径与诊断算法。
- 利用上述检测辅助抗真菌药物管理和监测,并预测治疗结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diagnosing invasive aspergillosis (IA) has long been challenging due to the inability to culture the causal Aspergillus agent from blood or other body fluids. This shortcoming has fuelled an interest in non-culture-based diagnostic techniques such as the detection of galactomannan (GM) in blood and bronchoalveolar lavage fluid, the detection of 1,3-β-d-glucan (BDG) in blood and the detection of Aspergillus DNA by PCR-based techniques. Past decades have witnessed important improvements in our understanding of the strengths and limitations of antigen assays and in the standardization of PCR-based DNA techniques. These assays are now being incorporated into care pathways and diagnostic algorithms; they help us to steward and monitor antifungal therapies and to predict treatment outcomes.
引用
- Maertens JA, Blennow O, Duarte RF, et al. The current management landscape: aspergillosis. J Antimicrob Chemother. 2016. PMID: 27880666
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。